Opsona Therapeutics (Ireland)

NCCN Guidelines Insights: Colon Cancer, Version 2.2018

Al B. Benson, Alan P. Venook, Mahmoud M. Al-Hawary et al. · Journal of the National Comprehensive Cancer Network · 2018 · 1K citations · Full text

Medicine, Oncology, Perioperative Medicine +17

Viral Inhibitory Peptide of TLR4, a Peptide Derived from Vaccinia Protein A46, Specifically Inhibits TLR4 by Directly Targeting MyD88 Adaptor-Like and TRIF-Related Adaptor Molecule

Tatyana Lysakova-Devine, Brian Keogh, Barry J. Harrington et al. · The Journal of Immunology · 2010 · 132 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I, Healthy Subjects Study of Intravenous OPN-305, a Humanized Anti-TLR2 Antibody

Mary M. Reilly, R. Matthew Miller, MA Thomson et al. · Clinical Pharmacology & Therapeutics · 2013 · 120 citations · Full text

Medicine, Immunology, Pharmacology +16

Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer’s disease

Claire McDonald, Edel Hennessy, Ana Rubio‐Araiz et al. · Brain Behavior and Immunity · 2016 · 116 citations

Life Sciences, Neurobiology, Neuroscience +17

Treatment With OPN-305, a Humanized Anti–Toll-Like Receptor-2 Antibody, Reduces Myocardial Ischemia/Reperfusion Injury in Pigs

Fatih Arslan, Jaco H. Houtgraaf, Brian Keogh et al. · Circulation Cardiovascular Interventions · 2012 · 107 citations · Full text

Life Sciences, Immunology, Pharmacology +15